Cancer diagnostics company Lucid Diagnostics Inc (Nasdaq:LUCD) said on Wednesday that it has priced its initial public offering (IPO) of 5,000,000 shares of its common stock.
All of the shares in the IPO are being offered by the company at a price of USD14.00 per share for expected gross proceeds of USD70m, before deducting underwriting discounts, commissions and other offering expenses.
The company has provided the underwriters with a 30-day option to purchase up to an additional 750,000 shares of common stock from Lucid at the initial public offering price less underwriting discounts and commissions.
For the offering, Cantor and Canaccord Genuity are acting as joint book-running managers. BTIG and Needham & Company are acting as co-lead managers. The offering is expected to close on or about 18 October 2021, subject to the satisfaction of customary closing conditions.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886